JP2002523435A5 - - Google Patents

Download PDF

Info

Publication number
JP2002523435A5
JP2002523435A5 JP2000567099A JP2000567099A JP2002523435A5 JP 2002523435 A5 JP2002523435 A5 JP 2002523435A5 JP 2000567099 A JP2000567099 A JP 2000567099A JP 2000567099 A JP2000567099 A JP 2000567099A JP 2002523435 A5 JP2002523435 A5 JP 2002523435A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000567099A
Other languages
Japanese (ja)
Other versions
JP2002523435A (ja
JP4361215B2 (ja
Filing date
Publication date
Priority claimed from IT1998RM000566A external-priority patent/IT1302307B1/it
Application filed filed Critical
Publication of JP2002523435A publication Critical patent/JP2002523435A/ja
Publication of JP2002523435A5 publication Critical patent/JP2002523435A5/ja
Application granted granted Critical
Publication of JP4361215B2 publication Critical patent/JP4361215B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000567099A 1998-09-01 1999-08-19 アセチルL−カルニチンおよびα−リポ酸を含む抗酸化組成物 Expired - Lifetime JP4361215B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT98A000566 1998-09-01
IT1998RM000566A IT1302307B1 (it) 1998-09-01 1998-09-01 Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
PCT/IT1999/000268 WO2000011968A1 (en) 1998-09-01 1999-08-19 ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID

Publications (3)

Publication Number Publication Date
JP2002523435A JP2002523435A (ja) 2002-07-30
JP2002523435A5 true JP2002523435A5 (enExample) 2005-12-22
JP4361215B2 JP4361215B2 (ja) 2009-11-11

Family

ID=11406116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000567099A Expired - Lifetime JP4361215B2 (ja) 1998-09-01 1999-08-19 アセチルL−カルニチンおよびα−リポ酸を含む抗酸化組成物

Country Status (28)

Country Link
US (1) US6365622B1 (enExample)
EP (1) EP1112005B2 (enExample)
JP (1) JP4361215B2 (enExample)
KR (1) KR20010079699A (enExample)
CN (1) CN1315835A (enExample)
AR (1) AR022076A1 (enExample)
AT (1) ATE228312T1 (enExample)
AU (1) AU773424B2 (enExample)
BR (1) BR9913288A (enExample)
CA (1) CA2341973C (enExample)
CZ (1) CZ2001541A3 (enExample)
DE (1) DE69904208T3 (enExample)
DK (1) DK1112005T4 (enExample)
EE (1) EE200100113A (enExample)
ES (1) ES2188214T5 (enExample)
HK (1) HK1039730A1 (enExample)
HU (1) HU229165B1 (enExample)
IL (1) IL141435A0 (enExample)
IS (1) IS5850A (enExample)
IT (1) IT1302307B1 (enExample)
MA (1) MA25284A1 (enExample)
NO (1) NO20010954L (enExample)
PL (1) PL212737B1 (enExample)
PT (1) PT1112005E (enExample)
SK (1) SK2632001A3 (enExample)
TN (1) TNSN99163A1 (enExample)
TR (1) TR200100610T2 (enExample)
WO (1) WO2000011968A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7828200A (en) 1999-09-23 2001-04-24 Juvenon Corporation Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
EP1248609A4 (en) * 1999-11-03 2007-08-01 Juvenon Inc METHOD FOR TREATING THE GOOD MEMORY TROUBLESHOOTING
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
DE10036797A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Verwendung von Kombinationen mit einem Gehalt an Carnitinen
CN1477958A (zh) * 2000-10-31 2004-02-25 高露洁-棕榄公司 组合物及方法
US20020076470A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
JP2010142237A (ja) * 2000-10-31 2010-07-01 Colgate Palmolive Co 組成物及び方法
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
JP2004519241A (ja) * 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム 高齢化に伴う生理的障害を改善し寿命を延ばす組成物
SE0102380D0 (sv) * 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
US6923960B2 (en) * 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
WO2003053336A2 (en) * 2001-12-19 2003-07-03 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
WO2003072052A2 (en) * 2002-02-22 2003-09-04 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
JP2006506361A (ja) * 2002-10-11 2006-02-23 クレアグリ, インコーポレイテッド カルニチンおよび酸化防止ポリフェノールの治療用組合せ
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
DE10258239A1 (de) * 2002-12-13 2004-06-24 Degussa Ag Formulierung enthaltend alpha-Liponsäure(-Derivate) als alleinigen Wirkstoff bei nichtchronischen alkoholinduzierten Intoxikationen
US20040265345A1 (en) * 2003-06-30 2004-12-30 Perricone Nicholas V. Treatment of skin damage using acetyl carnitine and lipoic acid
US7999003B2 (en) * 2003-08-26 2011-08-16 Mannatech, Incorporated Antioxidant compositions and methods thereto
US20050214413A1 (en) * 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
WO2005067972A1 (en) * 2003-12-31 2005-07-28 Integrative Health Consulting, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
EP1817022B1 (en) * 2004-11-24 2018-04-25 Hill's Pet Nutrition, Inc. Methods for increasing the immune response in an animal
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
DK1817058T3 (en) * 2004-11-24 2015-12-07 Hills Pet Nutrition Inc COMPOSITION FOR USE FOR IMPROVING THE hepatic clearance xenobiotics WITH AN ANIMAL
CA2592389C (en) 2004-12-29 2013-05-14 Hill's Pet Nutrition, Inc. Methods for inhibiting a decline in learning and/or memory in animals
JP5295567B2 (ja) * 2004-12-30 2013-09-18 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 高齢期の動物の生活の質を高めるための方法
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニSigma−Tau Industrie Farmaceutiche Riunite Societa Per Azioni 有痛性末梢糖尿病性神経障害の予防のためのアセチルl−カルニチン
AU2006267068B2 (en) 2005-07-14 2011-01-06 Hill's Pet Nutrition, Inc. Method for prolonging the life of animals
US8318954B2 (en) * 2006-02-23 2012-11-27 Nou Life Sciences, Inc. Cleavable carnitine compound
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
CN101057857B (zh) * 2006-04-21 2011-05-18 中国科学院上海生命科学研究院 一种预防与改善帕金森氏症的组合物及其制法
KR100811110B1 (ko) * 2007-02-21 2008-03-06 주식회사 디피아이 솔루션스 수분산성 α-리포산 캡슐 조성물을 함유하는 어류의 면역력증강용 사료첨가제 및 그 사용방법.
US20080226696A1 (en) * 2007-03-15 2008-09-18 Ben Treadwell Methods of improving learning abilities of aged companion animals
KR20090014568A (ko) * 2007-08-06 2009-02-11 (주)바이오제닉스 코팅된 알파리포산 입자, 이를 포함하는 조성물 및 그 제조방법
WO2009020317A2 (en) * 2007-08-06 2009-02-12 Biogenics, Inc. Stabilized antioxidant particles, composition comprising the same and method for preparing the same
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
KR100903549B1 (ko) * 2008-07-29 2009-06-23 주식회사 카이로제닉스 균질한 결정성의 아세틸-l-카르니틴과 티옥트산 칼륨염의 복합염, 이의 제조방법 및 이를 포함하는 약학적 조성물
JP2012508267A (ja) * 2008-11-11 2012-04-05 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ セルライトの処置に有用な化合物
EP2389931A1 (en) * 2010-05-21 2011-11-30 Raw Materials Internatinal LLC Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
PT2787969T (pt) 2011-12-07 2021-11-09 Allergan Inc Entrega eficiente de lípidos para o filme lacrimal humano utilizando um sistema de emulsão sensível ao sal
US20140371280A1 (en) * 2013-03-15 2014-12-18 Shinichi Okuyama Method of treating diabetic peripheral neuropathy through amendment of pre-neuronal diabetic coagulative micro-angiopathy and neuronal deficiency of mitochondrial ATP production, and through induction of neuronal regeneration
US20190290609A1 (en) * 2014-03-19 2019-09-26 Epitech Group S.P.A. Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
CA2965671A1 (en) 2014-10-24 2016-04-28 Robert Shorr Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
CA2967413C (en) 2014-11-25 2023-08-15 Allergan, Inc. Ophthalmic compositions containing omega-3 oils stabilized by antioxidants
EP3277273B1 (en) 2015-03-31 2020-02-26 Kolinpharma S.p.A. A composition for the treatment of neuropathies and/or neuropathic pain
ES2815552T3 (es) 2015-08-24 2021-03-30 Vitrolife Sweden Ab Medio de cultivo
EP3849542A1 (en) * 2018-09-10 2021-07-21 URIACH ITALY S.r.l. Composition comprising lipoic acid and vitamin d for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies
CN111467385B (zh) * 2019-01-24 2022-05-17 深圳市华大农业应用研究院 组合物在预防或治疗神经退行性疾病中的用途
EP3773012B1 (en) * 2019-04-18 2021-06-30 Simo Rasi Composition for use in prevention or reduction of oxidative stress and neurodegenerative diseases
US12208077B2 (en) 2021-04-06 2025-01-28 Celagenex Research (India) Pvt. Ltd. Synergistic composition for potentiating stabilized ATP
CN112999220B (zh) * 2021-04-07 2022-12-13 中国人民解放军南部战区总医院 α-硫辛酸在作为和/或制备金属β-内酰胺酶抑制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1997002041A1 (en) 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US5977162A (en) 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
EP1021177A4 (en) * 1997-02-04 2002-05-15 John V Kosbab COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress

Similar Documents

Publication Publication Date Title
BE2015C057I2 (enExample)
BE2016C007I2 (enExample)
BE2015C018I2 (enExample)
BE2014C017I2 (enExample)
BE2013C051I2 (enExample)
BE2013C020I2 (enExample)
BE2013C015I2 (enExample)
BE2012C036I2 (enExample)
BE2008C046I2 (enExample)
JP2002505904A5 (enExample)
BE1025464I2 (enExample)
BE2010C011I2 (enExample)
BE2008C047I2 (enExample)
BE2011C004I2 (enExample)
JP2002523435A5 (enExample)
JP2002524098A5 (enExample)
JP2002515309A5 (enExample)
IN2000MU00532A (enExample)
JP2002525145A5 (enExample)
JP2002505569A5 (enExample)
IN188710B (enExample)
JP2002526785A5 (enExample)
JP2002525782A5 (enExample)
BRMU7902607U2 (enExample)
FR2768833A3 (enExample)